While we have a default mindset, we can be nudged away from that default by prevailing conditions at any given time. To explore how automation can transform video creation, consider Wideo’s integration with Zapier, which allows for personalized video content generation triggered by user actions. What types of law practices benefit from automated video content? Highlight the benefits of video automation, such as time savings and improved client interaction. Template Customization: Use client data to personalize video templates. Automation supports legal practices in managing large volumes of client data efficiently. Automated videos can clarify the claims process and keep clients informed every step of the way. The publisher claimed they couldn't throw the changes away because it would take too much time to re-edit. Automation can merge seamlessly with your existing systems, enhancing workflow efficiency and data management. These businesses can support access to justice, but only when backed by strong governance and responsible financial management. This saves time and enhances client satisfaction.
They can also be internal links to other, related content on your site (think: keyword universe) to help with SEO. The meta description should be around 130-165 characters long and describe the piece in a way that will encourage searchers to click on it. Blasting out your content via email marketing, like posting on social media, improves the visibility of the content, establishes credibility and authoritativeness, and improves click-through rate. This means that the author should have a bio on your site and a dedicated page where all their content for your site can be found. A meta title can be different than the article title and will help it rank higher. Excessively long URLs can hurt your SEO. One way to keep people on your page and engaged with your content is to make it "snackable." This term refers to content that is nicely divided up into small, easily consumable sections that are well defined with subheads. This description will not help with SEO but should improve click-through rate.
patient.infoThe average age of patients in the study, 23, did not represent the population likely to take the drug, he added. Topol - who drew attention last year with a finding that Celebrex and its competitor, Vioxx, appeared to raise the risk of heart attacks - said the Bextra studies did not include enough patients to justify drawing a broad conclusion. If you liked this article so you would like to receive more info regarding promotion i implore you to visit our web site. Yet through publication in the leading dental journal, the research helped Bextra's marketers shift attention away from the F.D.A.'s negative findings. SRC:MixSentence, IDs:1CB5D976;485FA936;3AD5669B;AF24C528;430C4AF5;DE757C7F;4F45A2FE;24F2A662;99219F16;FC8C0D50;63624C40;F78D37A9;1F46BF33;4F03F29E;C54A2492;1FADB78C;0ECB4049;04EFBA12;6B520626;E73F66B8;EA15627F;F3096291;39C9A45B;CEC0943E;C0692D6E;48263096;62457DA4
If this is where clinical research is headed, that would be a terrible negative trajectory," he said. cannot release any information about the earlier pain studies that failed to sway regulators. Scirex executives did not return repeated phone calls. Editors at The Journal of the American Dental Association said the Scirex article was reviewed by at least three scientists. Moore, an associate editor of the journal, said the study was "carefully designed and rigorously performed." But Dr. "Even though the study lacked some important proof, the real problem is that in the dental literature, this will be read," Dr. The Bextra episode is just one example of the changing face of drug research. In the early 1990's, about 75 percent of the drug industry's clinical research dollars went to universities, according to a study by CenterWatch, a company that tracks clinical trials. Pharmacia was not trying to bypass the regulatory process, she said, adding that the company is in discussions with regulators to have Bextra approved for acute pain. "And dentists, who have to deal with trying to prevent or modulate pain, will be impressed." Judy Glova, a spokeswoman for Pharmacia, said the drug company stood behind the design and conclusions of the Scirex studies. Moore said he would have recommended that the journal reject the paper had he known that Bextra was not approved for acute pain. Yet when the ad agency paid $20 million for part-ownership of Scirex in 1999, a top Omnicom executive, Thomas L. "We have nothing to do with the design of clinical studies," said Pat Sloan, an Omnicom spokeswoman. By 2000, just 34 percent went to academic institutions, while the rest went to investigators working under the direction of either a private research firm like Scirex or a pharmaceutical company. Harrison, said he expected Scirex's research to produce positive results for drug company clients - results that would help speed new-drug applications, or N.D.A.'s, to the F.D.A. Because of confidentiality rules, the F.D.A. "Our goal," he said, "is to help ensure that all clinical studies and each patient accrued into a study can be assessed to support the N.D.A. Omnicom says it has no control over Scirex.